Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

Trial Details

NCT ID
NCT04686305
Phase
PHASE1
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • T-DXd
  • Durvalumab
  • Cisplatin
  • Carboplatin
  • Pemetrexed
  • Volrustomig
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Newport Beach, California, United States|33.61891,-117.92895
  • Orange, California, United States|33.78779,-117.85311
  • Santa Rosa, California, United States|38.44047,-122.71443
  • Westwood, Kansas, United States|39.04056,-94.6169

Key Eligibility Criteria

  • Histologically documented unresectable locally advanced/metastatic non-squamous NSCLC
  • Part 1: Progression after 1 or 2 lines of systemic therapy for recurrent or metastatic setting.
  • Part 3, Part 4 and Part 5: Patients must have tumors that do not harbor known genomic alterations or actionable driver kinases, for which approved …
  • Part 3, Part 4 and Part 5: Patient must be treatment-naïve for advanced or metastatic NSCLC. Patients who have received prior adjuvant, or neoadjuv…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →